Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

REGENECYTE

PreclinicalBiologic

SStemCyte, Inc.

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q3 2027

Phase 3Not yet recruiting

Post-COVID Condition

NCT07184385

Clinical

Trials by Indication[1]

Fatigue1 trial

Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

Available·SStemCyte, Inc.··NCT07332338

Post-COVID Condition1 trial

A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition

Not yet recruiting·SStemCyte, Inc.·Phase 3·NCT07184385·60 enrolled

Post-COVID Syndrome1 trial

Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome

Completed·SStemCyte, Inc.·Phase 2·NCT05682560·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for REGENECYTE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGENECYTE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGENECYTE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — StemCyte, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: SStemCyte, Inc.

Related News